Clinical Relevance of Routine Monitoring of Patient-reported Outcomes
Patient-reported outcomes
clinicians-reported outcomes
electronic patient-reported outcomes
oncology
quality of life
review
Journal
In vivo (Athens, Greece)
ISSN: 1791-7549
Titre abrégé: In Vivo
Pays: Greece
ID NLM: 8806809
Informations de publication
Date de publication:
Historique:
received:
21
08
2018
revised:
24
09
2018
accepted:
25
09
2018
entrez:
28
12
2018
pubmed:
28
12
2018
medline:
6
4
2019
Statut:
ppublish
Résumé
The National Cancer Institute Common Terminology Criteria for Adverse Events classification is the standard classification used by the physicians in oncology for reporting adverse events. This classification has evolved over the last years according to the emergence of new therapies. Reporting symptoms, quality of life (QoL) and toxicities via patient-reported outcomes (PROs) in clinical practice is not yet a standard of care, nevertheless many studies have been conducted recently to assess feasibility and impact of routine monitoring of PROs, which should enable for better management of toxicities and earlier detection of disease progression in a more patient-centered health care delivery system. The aim of this article was to discuss the advantages and limitations of both approaches, clinicians-reported outcomes and PROs. Growing evidence supports that the routine collection of PROs leads to improvement of QoL and overall survival of cancer patients.
Identifiants
pubmed: 30587597
pii: 33/1/17
doi: 10.21873/invivo.11433
pmc: PMC6364064
doi:
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
17-21Informations de copyright
Copyright© 2019, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.
Références
Psychooncology. 2000 May-Jun;9(3):203-13
pubmed: 10871716
Cancer Pract. 2002 May-Jun;10(3):147-54
pubmed: 11972569
J Clin Oncol. 2004 Feb 15;22(4):714-24
pubmed: 14966096
Lancet Oncol. 2006 Nov;7(11):903-9
pubmed: 17081915
Eur J Cancer. 2014 Mar;50(5):953-62
pubmed: 24424105
J Clin Oncol. 2015 Mar 10;33(8):910-5
pubmed: 25624439
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
Lancet Oncol. 2016 May;17(5):663-70
pubmed: 27083333
Am Soc Clin Oncol Educ Book. 2016;35:67-73
pubmed: 27249687
J Natl Cancer Inst. 2017 Sep 1;109(9):
pubmed: 28423407
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
Ann Oncol. 2017 Jul 1;28(suppl_4):iv119-iv142
pubmed: 28881921
N Engl J Med. 2017 Oct 5;377(14):1309-1312
pubmed: 28976860
Acad Med. 1997 Sep;72(9):798-800
pubmed: 9311323